Increased osteopontin protein expression may be correlated with poor prognosis in non-small-cell lung cancer: A meta analysis

Zhen-bo, SU; Zhao, Jianjun; Yu, Dujuan; Tu, Junwei; Zhu, Jing; Zhao, Jianping; Lin, Shiu‐Ru; Wang, Sai-Bin; Sheng, Yijun; Chen, Huijun; Tian, Junqiang; Zhang, Yi; Wang, Jing

doi:10.4103/0973-1482.150362

Cited by 10 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data are also consistent with previous observations by Collins et al (2012) who demonstrated that higher SPP1 expression is beneficial since it was associated with an improved outcome in patients with pancreatic cancer [42]. By contrast, several other investigations highlighted that high SPP1 levels were correlated with poor outcomes in many solid malignancies such as prostate cancer, lung cancer, gastric cancer and breast cancer [43][44][45][46]. For instance, Wong et al (2017) showed that the overexpression of SPP1 in bladder cancer patients with high T-stage and tumor grades was significantly associated with decreased patient survival time [47].…”

Section: Discussionsupporting

confidence: 91%

Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in Urothelial Bladder Cancer: A Bioinformatics Analysis

Nedjadi,

Ahmed,

Ansari

et al. 2023

Cancers

View full text Add to dashboard Cite

Secreted phosphoprotein-1 (SPP1) expression is differentially altered in many malignancies and could serve as a potential prognostic biomarker. Recent findings indicated that SPP1 possesses a broader role in bladder cancer (BC) pathogenesis than previously envisioned; however, the underlying mechanisms governing its expression, cellular localization, prognostic value and immune-related role in bladder cancer remain poorly understood. The expression and the prognosis value of SPP1 were assessed using immunohistochemistry (IHC) staining on a tissue microarray. SPP1 expression was correlated with the clinicopathological parameters, and survival analysis was calculated using a Kaplan–Meier plotter. Bioinformatics analysis of TCGA data was queried using UALCAN, CIBERSORT and TIMER datasets to decipher the biological processes enrichment pattern, protein–protein interactions and characterize tumor-infiltrating immune cells, respectively. IHC revealed that SPP1 expression is significantly associated with tumor type, stage, grade and smoking status. The Kaplan–Meier survival curve showed that low SPP1 expression is an unfavorable prognostic indicator in bladder cancer patients (p = 0.02, log-rank). The significant increased expression of the SPP1 level is associated with evident hypomethylation of the gene promoter in cancer compared to normal tissues in the TCGA-bladder dataset. Missense mutation is the most frequent genetic alteration of the SPP1 gene. Protein–protein interactions demonstrated that SPP1 shares the same network with many important genes and is involved in many signaling pathways and biological processes. TIMER reported a significant correlation between SPP1 expression and multiple immune cells infiltration. Furthermore, the expression of SPP1 was found to be positively correlated with a number of immune checkpoint genes such as PD-1 and CTLA4. The current investigation indicates that the SPP1 protein could serve as a prognostic biomarker and merit further investigation to validate its clinical usefulness in patients with bladder cancer.

show abstract

Section: Discussionsupporting

confidence: 91%

Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in Urothelial Bladder Cancer: A Bioinformatics Analysis

Nedjadi,

Ahmed,

Ansari

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…In a selection of 10 clinical cohort studies represented by a total of 1133 NSCLC patients, Shi et al showed a shorter overall survival in OPN-positive patients compared to that in OPN-negative patients with no significant differences between the Asian and the Caucasian groups, thus suggesting a role for OPN as a prognostic factor for NSCLC [102]. Moreover, the analysis by Hu et al of a cohort of six studies, with a total of 906 participants, of which 360 were MPM patients and 546 healthy individuals, showed that the diagnostic accuracy of OPN for MPM was comparable to that of the soluble mesothelin-related peptides (SMRP), the most promising serum biomarker for MPM [103].…”

Section: Systemic Opn Levels In Cancermentioning

confidence: 99%

Osteopontin at the Crossroads of Inflammation and Tumor Progression

Castello

Raineri

Salmi

et al. 2017

Mediators of Inflammation

139

132

View full text Add to dashboard Cite

Complex interactions between tumor and host cells regulate systemic tumor dissemination, a process that begins early at the primary tumor site and goes on until tumor cells detach themselves from the tumor mass and start migrating into the blood or lymphatic vessels. Metastatic cells colonize the target organs and are capable of surviving and growing at distant sites. In this context, osteopontin (OPN) appears to be a key determinant of the crosstalk between cancer cells and the host microenvironment, which in turn modulates immune evasion. OPN is overexpressed in several human carcinomas and has been implicated in inflammation, tumor progression, and metastasis. Thus, it represents one of the most attracting targets for cancer therapy. Within the tumor mass, OPN is secreted in various forms either by the tumor itself or by stroma cells, and it can exert either pro- or antitumorigenic effects according to the cell type and tumor microenvironment. Thus, targeting OPN for therapeutic purposes needs to take into account the heterogeneous functions of the multiple OPN forms with regard to cancer formation and progression. In this review, we will describe the role of systemic, tumor-derived, and stroma-derived OPN, highlighting its pivotal role at the crossroads of inflammation and tumor progression.

show abstract

“…Although OPN is not tumor-specific, its potential as a tumor biomarker has been demonstrated in several malignancies, including breast cancer [ 3 , 4 ]. Elevated OPN expression has been associated with poor survival of cancer patients with different tumor histotypes [ 5 – 8 ]. Moreover, high OPN plasma concentrations were found in patients with metastatic breast cancer compared to healthy volunteers [ 9 ], while a number of studies have demonstrated that OPN may be associated with breast cancer progression and metastasis [ 10 – 12 ].…”

Section: Introductionmentioning

confidence: 99%

Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group

Psyrri

Kalogeras

Wirtz³

et al. 2017

J Transl Med

View full text Add to dashboard Cite

BackgroundThe shift towards an earlier diagnosis of breast cancer (BC) highlights the need for biomarkers that would identify patients at risk for relapse and metastatic spread and indicate the potential value of additional treatment strategies. Osteopontin (OPN) is a matricellular protein that has been suggested to be a potential biomarker in BC. In the present study, we used archived BC patient samples to assess the clinical utility of OPN.Methods Formalin-fixed paraffin-embedded tumor tissue samples from 975 patients were collected from two large phase III randomized adjuvant chemotherapy trials (HE10/97 and HE10/00) that included patients with high risk BC. All tissue samples were assessed for ER, PgR, Ki67 and HER2 protein expression. OPN protein and mRNA expression was evaluated using immunohistochemistry and quantitative reverse transcription-polymerase chain reaction, respectively.ResultsOPN mRNA expression data were available for 814 patients, whereas OPN protein expression data were available for 546 patients. The majority of patients were ER/PgR-positive (78.3%), HER2-negative (76.5%) and Ki67-positive (55.2%) and had received adjuvant radiation therapy (76.8%) and hormonal therapy (81.1%). OPN mRNA expression was significantly associated with age (60.9% in high OPN tumors vs. 54.1% in low OPN tumors, p = 0.047), ER/PgR-negative status (25.7 vs. 17.2%, p = 0.004) and BC subtypes (p = 0.021). In addition, high OPN mRNA expression was significantly associated with reduced DFS (HR 1.26, 95% CI 1.00–1.59, Wald’s p = 0.050) and OS (HR 1.37, 95% CI 1.05–1.78, p = 0.019), while it retained its prognostic significance for both DFS (HR 1.39, 95% CI 1.10–1.77, p = 0.007) and OS (HR 1.54, 95% CI 1.61–2.05, p = 0.003) in the multivariate analysis.ConclusionsWe showed that high OPN mRNA expression is associated with decreased DFS and OS in a large cohort of BC patients treated with adjuvant chemotherapy in a clinical trial setting. Our results suggest that OPN may serve as a prognostic factor and a potential target for therapy. Trial registration Australian New Zealand Clinical Trials Registry; HE10/97 ACTRN12611000506998; HE10/00 ACTRN12609001036202Electronic supplementary materialThe online version of this article (doi:10.1186/s12967-017-1134-7) contains supplementary material, which is available to authorized users.

show abstract

Increased osteopontin protein expression may be correlated with poor prognosis in non-small-cell lung cancer: A meta analysis

Abstract: The present meta-analysis is consistent with the hypothesis that increased expression of OPN protein may be significantly associated with poor prognosis in patients with NSCLC.

Cited by 10 publications

References 1 publication

Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in Urothelial Bladder Cancer: A Bioinformatics Analysis

Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in Urothelial Bladder Cancer: A Bioinformatics Analysis

Osteopontin at the Crossroads of Inflammation and Tumor Progression

Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group

Contact Info

Product

Resources

About